Abstract
The ovaries are paired pelvic organs typically found below the bifurcation of the common iliac vessels lateral to the uterus. They are responsible for hormone secretion and the production of female reproductive cells. Histologically, the ovaries are composed of follicles embedded in a mesh of stroma formed of connective tissue and spindle cells and covered by a layer of surface epithelium. Abnormal proliferation of any of the tissue types can result in both benign and malignant ovarian tumors.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212–36. doi:10.3322/caac.20121.
Omura GA, Brady MF, Homesley HD, et al. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. J Clin Oncol. 1991;9:1138–50.
Ramirez I. The role of surgery in the management of epithelial ovarian cancer. Cancer Control. 2011;18:22–30.
Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010;363:943–53. doi:10.1056/NEJMoa0908806.
Jung SE, Lee JM, Rha SE, Byun JY, Jung JI, Hahn ST. CT and MR imaging of ovarian tumors with emphasis on differential diagnosis. Radiographics. 2002;22:1305–25.
Timmerman D, Ameye L, Fischerova D, et al. Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group. BMJ. 2010;341:c6839. doi:10.1136/bmj.c6839.
Spencer JA, Gore RM. The adnexal incidentaloma: a practical approach to management. Cancer Imaging. 2011;11:48–51. doi:10.1102/1470-7330.2011.0008.
Levine D, Brown DL, Andreotti RF, et al. Management of asymptomatic ovarian and other adnexal cysts imaged at US Society of Radiologists in Ultrasound Consensus Conference Statement. Radiology. 2010;256:943–54. doi:10.1148/radiol.10100213.
Spencer JA, Forstner R, Cunha TM, Kinkel K. ESUR guidelines for MR imaging of the sonographically indeterminate adnexal mass: an algorithmic approach. Eur Radiol. 2010;20:25–35.
Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, editors. AJCC cancer staging manual. 7th ed. New York: Springer; 2010.
FIGO Committee on Gynecologic Oncology. Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009;105:3–4.
Mironov O, Ishill NM, Mironov S, et al. Pleural effusion detected at CT prior to primary cytoreduction for stage III or IV ovarian carcinoma: effect on survival. Radiology. 2011;258:776–84.
Tempany CM, Zou KH, Silverman SG, Brown DL, Kurtz AB, McNeil BJ. Staging of advanced ovarian cancer: comparison of imaging modalities–report from the Radiological Diagnostic Oncology Group. Radiology. 2000;215:761–7.
Coakley FV. Staging ovarian cancer: role of imaging. Radiol Clin North Am. 2002;40:609–36. doi:10.1007/s00330-010-1886-4.
Forstner R, Sala E, Kinkel K, Spencer JA. ESUR guidelines: ovarian cancer staging and follow-up. Eur Radiol. 2010;20:2773–80.
Ricke J, Sehouli J, Hach C, Hanninen EL, Lichtenegger W, Feliz R. Prospective evaluation of contrast-enhanced MRI in the depiction of peritoneal spread in primary or recurrent ovarian cancer. Eur Radiol. 2003;13:943–9. doi:10.1148/radiol.2482070371.
Akin O, Sala E, Moskowitz CS, et al. Perihepatic metastases from ovarian cancer: sensitivity and specificity of CT for the detection of metastases with and those without liver parenchymal invasion. Radiology. 2008;248:511–7. doi:10.1148/radiol.10100162.
Rustin G, Tuxen M. Use of CA 125 in follow-up of ovarian cancer. Lancet. 1996;348(9021):191–2. doi:S0140673696240292 [pii].
Tuxen MK, Soletormos G, Dombernowsky P. Tumor markers in the management of patients with ovarian cancer. Cancer Treat Rev. 1995;21:215–45.
Folk JJ, Botsford M, Musa AG. Monitoring cancer antigen 125 levels in induction chemotherapy for epithelial ovarian carcinoma and predicting outcome of second-look procedure. Gynecol Oncol. 1995;57:178–82. doi:10.1006/gyno.1995.1121.
Patsner B, Orr Jr JW, Mann Jr WJ, Taylor PT, Partridge E, Allmen T. Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol. 1990;38:373–6. doi:10.1016/0090-8258(90)90076-W [pii].
Rubin SC, Hoskins WJ, Hakes TB, et al. Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 1989;160:667–71.
Low RN, Duggan B, Barone RM, Saleh F, Song SY. Treated ovarian cancer: MR imaging, laparotomy reassessment, and serum CA-125 values compared with clinical outcome at 1 year. Radiology. 2005;235:918–26.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2014 Springer Science+Business Media New York
About this chapter
Cite this chapter
Vargas, H.A., Di Paolo, P.L., Afaq, A., Akin, O. (2014). Ovarian Cancer. In: Akin, O. (eds) Atlas of Gynecologic Oncology Imaging. Atlas of Oncology Imaging. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-7212-4_1
Download citation
DOI: https://doi.org/10.1007/978-1-4614-7212-4_1
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4614-7211-7
Online ISBN: 978-1-4614-7212-4
eBook Packages: MedicineMedicine (R0)